The prevalence of obesity is continuously growing and has reached epidemic proportions. It is 16
receptors that detect these MAMPs are called pathogen recognition receptors (PRRs) and 84 include a diverse set of transmembrane (e.g. Toll-like receptors) (Takeda et al., 2003) , 85 cytosolic (e.g. NOD-like receptors) (Ting et al., 2008) and secreted receptors (e.g. collectins) 86 (Gupta and Surolia, 2007) . This allows the host to characterize the nature of the microbial 87 signal and respond appropriately. The resulting host response includes production of 88 antimicrobial peptides (Medzhitov and Janeway, 1997) , activation of adaptive immune cells 89 and production of resulting effector molecules including e.g. Immunoglobulin A (IgA) 90 (Macpherson and Uhr, 2004) . As a result of the continuous detection of microbes, host 91 defence molecules are continuously secreted and trapped in the overlaying mucus layer, 92 which allows the host to particularly control the composition and abundance of the mucosa-93 associated microbiota (Figure 1 ). Specific microbial characteristics such as capacity to adhere 94 to the mucus layer, oxygen tolerance, the ability to degrade host-derived glycans further 95 determine the unique composition of the mucosal microbiota (Van den Abbeele et al., 2011). 96
While mucosal microbes would be crucial for priming the immune system or increasing the 97 bioavailability of beneficial microbial metabolites at the intestinal surface, the luminal 98 microbiota have an important metabolic function. 99 Given the fact that humans closely interact with their co-evolved luminal and mucosal 100 intestinal microbiota, there is great interest in dietary interventions with e.g. prebiotic 101
compounds that are able to modulate both the luminal and mucosal microbial composition 102 and activity (Langlands et Over the last few years, the research group of Nathalie Delzenne produced several 108 groundbreaking papers regarding the onset of obesity and its related metabolic disorders. In 109 several studies, one investigated, the impact of a high-fat diet on the intestinal microbiota and 
. TLR-4 is only in low levels expressed on the apical side of the 117 epithelium while NOD-1 is expressed inside the cell. In this way, LPS is not detected on the 118 apical side where it merely derives from the commensal mucosa-associated microbes but on 119 locations where its presence may derive from potentially dangerous microbes. The increased 120 permeability which is caused by the high-fat diet leads to LPS leakage trough the gut wall 121 ultimately leading to increased LPS levels in the blood (endotoxemia of Lactobacillus F19, the FIAF stimulatory effect was attributed to a secreted microbial 215 factor, which was however not identified in the study. In addition, conventionalization of 216 mice with Lactobacillus F19 increased native FIAF levels in blood plasma, and resulted in 217 decreased fat storage and increased blood VLDL levels. 218
Summarized, although FIAF is an interesting molecule to focus on for prebiotic treatment, its 219 functionality largely depends on the site of production, isoform appearance and final target 220 organs. Until now, the most dominating effect of microbial FIAF modulation is not identified 221 yet and needs further investigation with relevant models. 222 223
Prebiotics that alter energy intake through satiety signals 224 225
Prebiotics may also be used to decrease appetite by modulation of specific hormones involved 226 in appetite and satiety. Leptin is a hormone mainly produced by adipose tissues and inhibits 227 food intake. Prebiotic substrates such as chitosan decrease the production of leptin in 228 adipocytes in high fat diet-induced obese mice (Neyrinck et al., 2009) , although the exact 229 mode-of-action is not known. In addition, leptin was also decreased in rats weaned with 230 inulin-containing high fiber diets (Maurer et al., 2009 propionate that is needed to induce the cholesterol and lipid lowering effect is 10 to 100 fold 300 higher for human than for rat hepatocytes (Lin et al., 1995) . 301
Hepatic lipogenesis is not only regulated by short chain fatty acids, but also by serum glucose 302 and insulin levels (Towle, 2001 ). Enhanced sugar uptake has been observed in presence of gut 303 bacteria compared to germ-free conditions, which can be explained by several mechanisms. 304
First of all, the presence of an intestinal microbial community leads towards an increase in the 305 amount of capillaries that underlie the small intestinal epithelium (Hooper et al., 2002) . 306
Secondly, host monosaccharide transporters are induced by the polysaccharide-processing 307 activity of the microbiota, as was demonstrated by studies with germ-free mice colonized with 308 B. thetaiotaomicron (Hooper et al., 2001 ). The monomers generated from indigestible 309 polysaccharides are delivered as substrates for lipid production in the liver. Besides, they may 310 also activate the lipogenic enzymes in the liver by ChREBP-and SREBP-1-mediated 311 mechanisms (Bäckhed et al., 2004) . Hence, the polysaccharide-degrading potential of an 312 intestinal microbial community may be an important determinant for hepatic lipid production. 313
In obese ob/ob mice, the intestinal microbial community is enriched for genes that are able to 314 harvest calories from complex plant-derived polysaccharides compared to lean mice. These 315 genes encode for enzymes involved in sugar degradation, sugar transport and acetate and 316 butyrate production (Turnbaugh et al., 2006) . 317 We conclude that the potential influence of intestinal microbiota and prebiotics on lipid and 318 cholesterol production in the host is a complicated process which involves several nutrients, 319 target organs and signalling pathways. More investigation is warranted to identify the 320 dominating mechanism by which prebiotic modulation of the intestinal microbial community 321 may contribute to lipid and cholesterol lowering effects. 322 323
Part 3: Prebiotic modulation of glucose and insulin metabolism 324 325
As mentioned before, intestinal bacteria can impact food intake and lipid metabolism, but 326 may also be involved in carbohydrate maintenance and disturbances thereof, such as insulin 327 resistance. Insulin resistance is the fundamental defect in type 2 diabetes, a disease that 328 afflicts 6% of adult Americans, up from 3% in the early 1970s (Taubes, 2009 interindividual variability of our holobiont is a key factor for the success of a given strategy. 419
For instance, Walker et al. (2011) recently showed a strong variation in terms of microbial 420 modulation among human subjects in response to prebiotic supplementation. As a 421 consequence, the management of the intestinal microbiota with the aim of improving human 422 health will optimally require a prior characterization of the microbiota, i.e. the concept of 423 personalized health-care. In this respect, several options may be available. When the 424 necessary genes/species/strains are present, one may target them through specific prebiotics. 425
If not present, the so-called synbiotic approach could be a valuable solution: addition of 426 specific bacteria with a metabolic capability of interest (e.g. probiotics but also microbes 427 beyond the current definition such as butyrate producing species -Eubacterium rectale, Gautier, L., Hansen, T., Hattori, M., Hayashi, T., Kleerebezem, M., Kurokawa, K., Leclerc, 456 M., Levenez, F., Manichanh, C., Nielsen, H.B., Nielsen, T., Pons, N., Poulain, J., Qin, J., 457
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